Vinyas Innovative Technologies Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/t4pt3027d7jf3ewn3xxjduex.pdf

Key Takeaways


Revenue & Profitability

Sumukh Narendra: "I would say that we are very confident that we would remain in the margin profile between 9% to 11%. There is also operational efficiencies as well as programs maturing which has allowed us to reach this margin profile. The next two, three years, I don't see the margin profile changing."

Order Book & Demand Visibility

Sumukh Narendra: "The risk is I would say the risk associated with any kind of a defense program, all these defense programs, there are push-outs. So, the major risk that we foresee is delays in the programs getting sanctioned and delays in the program getting to critical stage where we get into a series manufacturing stage."

Segment Mix & Vertical Expansion

VerticalRevenue ShareCommentary
Defense & Aerospace78%Dominant franchise; commercial aerospace entry adds a new sub-vertical within the segment.
Industrial18.4%Showed remarkable growth; details on specific sub-segments were not disclosed.
Medical Devices₹6.7 croresFresenius Kabi manufacturing agreement signed; first-phase certifications complete, ramp-up expected through FY26.

Operations & Supply Chain

Sumukh Narendra: "We are what we call as a high-mix, high-complexity assembly house. So, we make critical subsystems for our customers. And we focus on fairly complex both PCB assemblies as well as system assemblies for our customers. And we focus on low and medium volume manufacturing."

Margin Structure & Outlook

Sumukh Narendra: "The mix. So, all of which end of the day is a build-to-print manufacturing that we do. The differentiating factor is we do high mix, low volumes. So, here, the complexity is higher, and we do lower volumes of the manufacturing. But at the end of the day, it is a build-to-print operation that we are doing. So, that is the reason for our margin profile."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth25% to 30% year-on-year growthFY26
EBITDA marginRemain within 9% to 11% bandFY26 and next 2-3 years
Order inflow₹600 to ₹750 crores of new ordersFY26
Order bookGrow confirmed order book to ₹1,500-₹1,600 croresBy end of FY26
Optimal capacity utilizationFull optimal utilization of current capacityFY27
Working capital ratioReach approximately 30% of salesNo specific date; target stated
Fresenius Kabi rampFirst few thousand units shipping; ramp through the yearFY26
Commercial aerospace OEM updatesFurther updates on additional OEM qualificationsFirst half of FY26

Key Metrics

MetricQ4 FY25
Revenue (FY25)₹396.6 cr, +25% YoY from ₹317 cr in FY24
Revenue (H2 FY25)₹247.1 cr, +37% YoY
EBITDA (FY25)₹44.4 cr, +22% YoY, margin ~11%
EBITDA (H2 FY25)₹26.7 cr, +32% YoY, margin ~11%
Net profit (FY25)₹19.4 cr, +27% YoY from ₹15.3 cr in FY24
Net profit (H2 FY25)₹12.4 cr, +28% YoY
EPS (FY25)₹15.43
EPS (H2 FY25)₹9.86
Revenue growth target (FY26)25%
EBITDA margin target (FY26)9% to 11%
Order book~₹1,018 cr as on May 30, 2025
New orders booked (FY25)₹737 cr
Order inflow expected (FY26)₹600 to ₹750 cr
Expected order book by end of FY26₹1,500 cr to ₹1,600 cr
Operating cash flow (FY25)₹8.8 cr positive
Defense & Aerospace revenue share78% of total revenue
Industrial revenue share18.4% of total revenue
Medical devices revenue₹6.7 cr
Export orders share22% to 23% of total orders
Current capacity utilization~35%
Revenue potential from current capacity₹1,200 cr to ₹1,400 cr
Order book execution timeline12 to 18 months
Supply chain dependency on Israel27% to 30% of programs
Target working capital~30% of revenue
Make in India share of order book~80%
Expected yearly CAPEX for critical programs₹2 cr to ₹3 cr